Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for cancer treatment-related oropharyngeal mucositis pain
ACTRN12619000108112Phase 3Not yet recruiting
- Sponsor
- Monash Health
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine and midazolam in oropharyngeal mucositis (OM) (2 arms), sponsored by Monash Health. Primary endpoints: Composite primary outcome: pain, analgesic use, and oral intake, Ketamine metabolism by serum assay and 1 more. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
ketaminemidazolam
03
Conditions
oropharyngeal mucositis (OM)
Beyond the preview
Go deeper on ACTRN12619000108112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000108112.